SEC Filing Summary: AcelRx Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on May 4, 2016, reporting events occurring on May 2, 2016. The filing serves as a current report to announce a conference call conducted by senior management to provide a business update and discuss financial results for the quarter ended March 31, 2016.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics were discussed during the referenced conference call, the transcript of which is attached as Exhibit 99.1, but are not detailed within the body of this 8-K report.
Material Changes
No material changes to financial position or operations are quantified in this document. The filing solely references the discussion of first-quarter 2016 results during the conference call.
Guidance, Outlook, and Risks
Management provided a business update and discussed financial results during the May 2, 2016 conference call. The filing does not contain specific guidance, outlook figures, risk factors, or details on contingencies and unusual items within the report text itself.
Investor Verification Checklist
- Review Exhibit 99.1 (Transcript of the First Quarter 2016 Financial Results Conference Call) for specific financial figures and management commentary.
- Verify the company name discrepancy: The request metadata lists "TALPHERA, INC.", but the filing is for "ACELRX PHARMACEUTICALS, INC."
- Confirm the exact date of the conference call (May 2, 2016) against the filing date (May 4, 2016).
- Check subsequent filings for the actual 10-Q report containing audited or reviewed financial statements for the quarter ended March 31, 2016.